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The Withdrawal Assessment Tool–1 (WAT–1): An Assessment Instrument for
Monitoring Opioid and Benzodiazepine Withdrawal Symptoms in Pediatric
Patients
Abstract
Objective: To develop and test the validity and reliability of the Withdrawal Assessment Tool–1 for
monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients.
Design: Prospective psychometric evaluation. Pediatric critical care nurses assessed eligible at-risk
pediatric patients for the presence of 19 withdrawal symptoms and rated the patient’s overall withdrawal
intensity using a Numeric Rating Scale where zero indicated no withdrawal and 10 indicated worst
possible withdrawal. The 19 symptoms were derived from the Opioid and Benzodiazepine Withdrawal
Score, the literature and expert opinion.
Setting: Two pediatric intensive care units in university-affiliated academic children’s hospitals.
Patients: Eighty-three pediatric patients, median age 35 mos (interquartile range: 7 mos−10 yrs),
recovering from acute respiratory failure who were being weaned from more than 5 days of continuous
infusion or round-the-clock opioid and benzodiazepine administration.
Interventions: Repeated observations during analgesia and sedative weaning. A total of 1040 withdrawal
symptom assessments were completed, with a median (interquartile range) of 11 (6–16) per patient over
6.6 (4.8−11) days.
Measurements and Main Results: Generalized linear modeling was used to analyze each symptom in
relation to withdrawal intensity ratings, adjusted for site, subject, and age group. Symptoms with high
redundancy or low levels of association with withdrawal intensity ratings were dropped, resulting in an
11-item (12-point) scale. Concurrent validity was indicated by high sensitivity (0.872) and specificity
(0.880) for Withdrawal Assessment Tool–1 > 3 predicting Numeric Rating Scale > 4. Construct validity
was supported by significant differences in drug exposure, length of treatment and weaning from
sedation, length of mechanical ventilation and intensive care unit stay for patients with Withdrawal
Assessment Tool–1 scores > 3 compared with those with lower scores.
Conclusions: The Withdrawal Assessment Tool–1 shows excellent preliminary psychometric
performance when used to assess clinically important withdrawal symptoms in the pediatric intensive
care unit setting. Further psychometric evaluation in diverse at-risk groups is needed.
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Abstract
Objective—To develop and test the validity and reliability of the Withdrawal Assessment Tool Version 1 (WAT-1) for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric
patients.
Design—Prospective psychometric evaluation. Pediatric critical care nurses assessed eligible atrisk pediatric patients for the presence of 19 withdrawal symptoms and rated the patient’s overall
withdrawal intensity using a numeric rating scale (NRS) where 0 indicated no withdrawal and 10
indicated worst possible withdrawal. The 19 symptoms were derived from the Opioid and
Benzodiazepine Withdrawal Score (OBWS), the literature and expert opinion. Setting: Two Pediatric
Intensive Care Units (PICU) in university-affiliated academic children’s hospitals.
Patients—83 pediatric patients, median age 35 months (IQR: 7months -10 years), recovering from
acute respiratory failure who were weaning from more than 5 days of continuous infusion or roundthe-clock opioid and benzodiazepine administration.
Interventions—Repeated observations during analgesia and sedative weaning. A total of 1040
withdrawal symptom assessments were completed, with a median (IQR) of 11 (6-16) per patient over
6.6 (4.8-11) days.
Measurements and Main Results—Generalized linear modeling was used to analyze each
symptom in relation to withdrawal intensity ratings, adjusted for site, subject and age group.
Symptoms with high redundancy or low levels of association with withdrawal intensity ratings were
dropped, resulting in an 11-item (12-point) scale. Concurrent validity was indicated by high
sensitivity (.872) and specificity (.880) (WAT-1 ≥3 predicting NRS ≥4). Construct validity was
supported by significant differences in drug exposure, length of treatment and weaning from sedation,
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length of mechanical ventilation and intensive care unit stay for patients with WAT-1 scores ≥3
compared to those with lower scores.
Conclusions—The WAT-1 shows excellent preliminary psychometric performance when used to
assess clinically important withdrawal symptoms in the PICU setting. Further psychometric
evaluation in diverse at-risk groups is needed.
Keywords
drug withdrawal symptoms; opioid analgesia; benzodiazepine; sedation

Introduction
Patients in the pediatric intensive care unit (PICU) frequently receive prolonged analgesia and
sedation to provide pain relief and blunt physiological stress responses.1-3 Iatrogenic
withdrawal occurs when these drugs are then stopped abruptly or weaned too rapidly, causing
central nervous system hyperirritability, autonomic system dysregulation, gastrointestinal
dysfunction and motor abnormalities.4;5 The risk of withdrawal is influenced by the length and
amount of exposure to opioids and benzodiazepines, rising to over 50% after 5 days of
continuous infusion or around-the-clock administration.6 Iatrogenic withdrawal can
complicate medical treatment, cause distress to patients and families and prolong recovery and
hospital stay.1;4;7 Although the prevalence of iatrogenic withdrawal is unknown, one survey
found it was a problem in 94% of PICUs. 8
Despite the fact that iatrogenic withdrawal has been observed for over 20 years in infants and
children receiving intensive care, a gold standard for the diagnosis or a measure of withdrawal
symptom intensity does not exist. Without a measurement tool, early diagnosis and systematic
evaluation of the effectiveness of treatment is difficult.2;5;6;9
Current clinical assessment tools are derivatives of the Finnegan Neonatal Abstinence Score
(NAS) developed in 1975 for the assessment of withdrawal symptoms in otherwise healthy
neonates with prenatal drug exposure.10 Our previous investigation of the Opioid and
Benzodiazepine Withdrawal Score (OBWS) provided preliminary validity and reliability of a
withdrawal assessment measure for use with infants and young children in intensive care
settings. 6;11 When tested, we found that sensitivity and specificity of the OBWS were only
moderate compared to nurses’ clinical judgment of withdrawal intensity and we identified
several usability difficulties, including the need for further training and improved inter-rater
reliability, confusion over when to assess the patient and the burden of the frequency of
assessment.
The Neonatal Withdrawal Index (NWI) 12 uses a different approach and has demonstrated
improved diagnostic accuracy for detecting withdrawal in neonates with perinatal drug
exposure. The NWI is performed only twice per day and involves assessment of a brief list of
key withdrawal signs and symptoms before, during and after a routine standard physical
assessment and caregiving procedure. This has advantages over previous methods of fourhourly observation of the patient in a ‘resting’ state in terms of ease of use and efficiency.
Moreover, it minimizes variability associated with difficulty in defining a resting state,
standardizes the observation, and reduces the bias that occurs with frequent serial measurement.
We hypothesized that the procedures and structure of the NWI could provide the basis for a
new method of iatrogenic withdrawal assessment that had improved reliability, validity, and
ease of use in diagnosing withdrawal in older infants and children receiving intensive care. We
describe here the development and preliminary psychometric evaluation of the new Withdrawal
Assessment Tool - Version 1 (WAT-1) for use with critically ill children who are exposed to
opioids and benzodiazepines for prolonged periods.
Pediatr Crit Care Med. Author manuscript; available in PMC 2009 November 10.
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Material and Methods
Design
A multicenter prospective repeated measures study was conducted to evaluate and refine an
instrument developed to assess iatrogenic withdrawal symptoms in pediatric critical care
patients. Psychometric evaluation of the new measure included examining response
distributions overall and by age, inter-item redundancy, factor structure, and construct validity
by comparing scores across groups that were expected to differ (known-groups validity), and
analyzing the association of scores with other clinical variables (e.g., amount of drug exposure
and length of weaning) hypothesized to be indicative of withdrawal severity (concurrent and
predictive validity).
Patient Enrollment
The study was conducted within the context of a clinical trial testing a sedation management
protocol in pediatric patients (2 weeks to 18 years of age) supported on mechanical ventilation
for acute respiratory failure in the PICU of two children’s hospitals (Children’s Hospital
National Medical Center, Washington, DC; Children’s Hospital of Wisconsin, Milwaukee,
WI).13 Both PICUs are large (22-24 bed) university-affiliated regional referral centers. Neither
site had a structured sedation weaning policy in place. The institutional review boards at both
sites approved the study. Consent for data collection was obtained from all parents/guardians.
Data were collected from February 2004 to April 2006.
All patients exposed to greater than 5 days of continuous infusion or regular around-the-clock
dosing of opioids were assessed for withdrawal symptoms twice daily at 8 am and 8 pm (and
at other times if clinically indicated) from the day that opioid weaning started until 72 hours
after the last opioid dose.1 The morning and the highest other score were used in analyses.
Patients exited the study at PICU discharge or after 28 days.
Instrument Description
The 19 symptoms of opioid and benzodiazepine withdrawal were derived from the OBWS,
documented in the withdrawal literature1;4 and supported by our previous study of withdrawal
symptoms in the PICU setting.11 The 19-item assessment consisted of (1) a review of the
patient’s record for the past 12 hours, (2) direct observation of the patient for 2 minutes, (3)
patient assessment during a progressive stimulated14 exam routinely performed to assess level
of consciousness at the beginning of each 12-hour shift, and finally (4) assessment of poststimulus recovery. The procedure for the standard progressive stimulation has been previously
reported14. During normal cares, the nurse first calls the patient’s name in a calm voice. If the
patient does not respond, the nurse calls the patient’s name and gently touches the patient’s
arm or leg. If the patient still does not respond, the nurse would assess the patient during a
planned noxious procedure, e.g., endotracheal suctioning or repositioning. Patient data
assessed from the previous 12 hours included 5 items: any loose or watery stools, any vomiting/
wretching/gagging, temperature > 37.8, respiratory rate greater than the child’s baseline,
suctioning more than once every two hours. Patient data assessed during the 2-minute prestimulus/quiet observation included 5 items: distressed state behavior, any tremor, sweating,
uncoordinated or repetitive movements, yawning or sneezing. Patient data assessed during the
1-minute progressive stimulus observation included 8 items: startle to touch, pupils greater
than 4mm, increased muscle tone, distressed state behavior; any tremor, sweating,
uncoordinated or repetitive movements, yawning or sneezing. The post-stimulus recovery data
included 1 item - the time to regain a calm state. Patients received one point for any of the
observations. Time to regain a calm state was scored 0 points for 0-2 minutes; 1 point from
2-5 minutes and 2 points for more than 5 minutes.
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Bedside nurses received training by the clinical nurse specialist on how to evaluate the presence
or absence of each of the 19 symptoms. Training consisted of a didactic review of the data
collection instrument followed by completion of a post-test. Inter-rater agreement for
withdrawal assessment ratings was established at the start of the study, and re-evaluated every
three months by simultaneous scoring by the clinical nurse specialist and the patient’s bedside
nurse. There was good inter-rater reliability for the 30 sets of paired ratings (Cohen’s kappa
= .80; ICC= .98).
Nurses were also asked to give, based on their clinical experience and judgment, a single overall
rating of withdrawal severity on a 0 to 10 numeric rating scale, with zero indicating no
withdrawal and 10 indicating the worst possible withdrawal symptoms, Nurses’ clinical
judgment of withdrawal intensity is the current standard of care.
Additional Data
Demographic and clinical data included site, age, ethnicity, mortality risk (PRISM III)15,
functional morbidity and cognitive impairment,16 cumulative and peak daily opioid dosage
(morphine equivalents per kilogram of body weight), cumulative and peak daily
benzodiazepine dosage (midazolam equivalents per kilogram of body weight) and
administration of any other analgesia, sedation or psychoactive medications. Conversion of
opioids and benzodiazepines to morphine and midazolam equivalents was performed
according to standard methods.17 Length of mechanical ventilation, length of PICU stay and
length of hospital stay, all as number of days, were calculated after discharge or 28 days.
Data Analysis
Descriptive statistics such as mean and standard deviation, or median and interquartile range,
were computed for all demographic and clinical variables, and examined as to whether they
differed by site. The median (IQR) length of the pre-weaning and weaning phases of opioid
and benzodiazepine therapy were computed. The start of the weaning period was defined as
the first date of a decrease in daily dosage >10% after 5 consecutive days of opioid treatment.
All analyses comparing groups were conducted using chi-square for categorical variables or
one-way ANOVA or its non-parametric equivalent, the Mann-Whitney U test, for
continuously-distributed variables. Most statistical analyses were performed using SPSS 15
(SPSS Inc, Chicago, IL). For analyses that included multiple observations on the same patient,
we used SUDAAN v. 9.0 analysis software (Research Triangle Institute, NC) to account for
potential intra-cluster correlation of data within site and within patient.
To evaluate the utility of each withdrawal symptom and identify any that could be dropped,
we first examined the inter-item agreement between pre-stimulus and stimulus ratings of the
same symptoms (state, tremor, sweating, movement, yawning) using kappa coefficient to
determine level of redundancy. A high kappa (>.65) indicated redundancy between the prestimulus and stimulus rating of a particular symptom, and only one of the two was chosen to
be retained for that symptom. In addition, we examined the prevalence of each symptom across
groups that we expected to differ based on nurses’ clinical impression. Using data from all
observations, we compared symptom prevalence across the following three groups using the
chi-square test in SUDAAN: those with NRS of 0 (no withdrawal), 1-3 (possibly in
withdrawal), and 4 or higher (top 20th percentile of scores, likely in withdrawal). We assessed
whether any symptoms had relatively high prevalence among the “no withdrawal” group or
did not differentiate the “no withdrawal” and “likely in withdrawal” groups, indicating that
these symptoms may not be specific to withdrawal. We also examined the level of missing data
for each item to identify those symptoms that may be more difficult to assess.
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After dropping redundant, non-specific, or difficult to assess items, exploratory factor analyses
were performed on the remaining items using principal components analysis with varimax
rotation to examine structural validity of the new Withdrawal Assessment Tool (WAT-1).
Based on a scree plot of initial eigenvalues, we examined 3-factor and 4-factor solutions for
the total data set containing all assessments, for each age group separately, and for two data
subsets created by randomly selecting a single record per patient.
Construct validity of the WAT-1 was evaluated by examining the degree to which peak WAT-1
scores per patient correlated with other indicators of the likelihood of withdrawal, including
pre-weaning cumulative opioid and benzodiazepine exposure, analgesia and sedative treatment
during weaning, and the duration of weaning. As the data distributions were often skewed for
these variables, we examined zero-order correlations among variables by generating
Spearman’s rho coefficients in SPSS.

Results
Patient characteristics
Among a total of 245 pediatric patients with acute respiratory failure supported on mechanical
ventilation, data were excluded for 26 patients who died and for 4 who did not commence
weaning from analgesia or sedation during the 28 day study period. Of the remaining 215
patients, 117 (54.4%) were identified as at risk for withdrawal (>5 days of regular opioid
administration), and 83 of them (71%) had withdrawal assessment data for inclusion in the
analyses. In 34 cases, patients at-risk for withdrawal had no assessments obtained due to PICU
transfer (7 cases) or clinical oversight (26 cases). There were no significant differences in
demographic characteristics between the at-risk patients with withdrawal assessments and
those without, but assessed patients had greater cumulative opioid (median (IQR): 48.2
(25.5-84.3) vs 7.5 (4.5-18.7) mg/kg; p<.001) and benzodiazepine (median (IQR): 7.6 (4.2-10.4)
vs 2.3 (1.0-3.5) mg/kg; p<.001) exposure, longer lengths of mechanical ventilation (median
(IQR)=9.9 (6.7-13.8) vs 7.1 (4.6-9.3) hours; p=.004) and PICU stays (median (IQR)=14.0
(10.0-22.5) vs 9.5 (7.0-17.0) days; p=0.015) than non-assessed patients.
Clinical and demographic characteristics of the study patients are shown in Table 1. The
demographic characteristics of patients from the two sites (site 1 n=47, site 2 n=36) differed
only in race (site 1=62% African American vs. site 2=36%, p<0.05).
Opioid and benzodiazepine weaning
Characteristics of opioid and benzodiazepine exposure and weaning are shown in Table 2. The
speed of opioid weaning varied considerably across patients, with one-third characterized by
consistent decreases in dosage of variable increments until weaning was completed, another
third characterized by multiple decreases and increases in dose during the weaning period, and
the final third having single dosage decreases of greater than 25%, some of which were
followed by periods where the weaning was slowed or halted.
During the weaning period, 32 (39%) patients received 1 to 3 other non-opioid analgesic or
sedative drug. However, only 2 drugs, ketamine and chloral hydrate were received by more
than 10% of patients. Patients who received these other drugs had greater exposure to opioids
(mean peak dose ± SD: 10.4 ± 4.8 vs 6.4 ± 3.9 mg/kg; p=.006; cumulative dose: 77.8 ± 49.3
vs 49.7 ± 40.2 mg/kg; p=.009), but there were no differences in length of the pre-weaning or
weaning periods or in benzodiazepine dose or duration compared with patients who were not
given other drugs. There were no differences in mean length of opioid or benzodiazepine
therapy or weaning and no differences in the mean peak or cumulative opioid doses between
the two sites.
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Examination of individual withdrawal symptoms
A total of 1040 withdrawal symptom assessments were completed, with a median (IQR) of 11
(6-16) per patient over 6.6 (4.8-11) days. Concurrent NRS withdrawal intensity ratings were
performed for 816 (78.3%) of the assessments. Table 3 shows the overall and age group-specific
prevalence rates for each symptom. There was only a marginal age effect for the startle-totouch symptom (chi-square=5.1, p=0.085).
The inter-item analyses revealed redundancy between the pre-stimulus and stimulus ratings
for sweating, uncoordinated/repetitive movement, tremor, yawning, and behavioral state, with
kappas ranging from .65 to .91 and crude percent agreement ranging from 92.2 to 98.1%.
Redundant items were dropped from either pre-stimulus or stimulus observations to reduce
patient disturbance and increase ease of symptom assessment (Table 3). Symptoms that
occurred with relatively high prevalence among those with NRS of 0, or that least differentiated
patients that received higher NRS withdrawal intensity scores (top 20th percentile) from those
with lower scores, included elevated respiratory rate, suctioning, and dilated pupils. Therefore,
these three items were dropped. The resulting measure consisted of 11 items (12-point) scale,
which we henceforth refer to as the WAT-1 (Table 4.). The correlation between the 19 original
symptoms and the more parsimonious WAT-1 was .947.
Factor structure
A 4-factor solution provided the best overall conceptual fit, explaining 58% of the variance in
analysis of all WAT-1 assessments. Motor-related symptoms (tremor, uncoordinated/repetitive
movements, muscle tone, and startle) comprised the factor that accounted for the most variance.
The second factor was comprised of behavioral state (pre-stimulus state and return to calm
state), the third factor was autonomic related (temperature and sweating), and the fourth factor
was comprised of gastrointestinal symptoms (stooling, vomiting) and yawning. The
components of the factor solutions varied slightly by age group and explained a total of 61%
(0-2 years), 65% (2.1-6 years) or 56% (>6 years) of the variance. The item factor loadings were
slightly different for children over 6 years of age compared to the younger age groups. For
example, in the older age group, motor and state related symptoms loaded on the same factor
and yawning and startle did not meet the threshold for inclusion (factor loadings ≥.40) in any
factor.
Construct validity
There was a high degree of convergence between the WAT-1 total scores and withdrawal
intensity ratings (Spearman’s rho coefficient = .80). Examination of receiver-operator
characteristic curves revealed that a WAT-1 score of 3 or higher had the best sensitivity and
specificity in relation to an intensity rating indicating clinically significant withdrawal, i.e., 4
or higher (.872 and .880; Figure 1).
We found that the 53 (64%) patients with higher peak WAT-1 scores (≥3) had greater
cumulative opioid doses and longer duration of opioid treatment prior to tapering (Figure 2)
compared to the 30 (36%) patients whose symptoms were less severe (WAT-1 < 3; Figure 2).
Peak WAT-1 scores for each patient correlated moderately with the length of opioid therapy
(r=.23, p=.04) and benzodiazepine therapy (r=.23, p=.04) prior to weaning and with the length
of opioid weaning (r=.33, p=.003). Opioid weaning was completed in more patients with peak
WAT-1 scores < 3 compared to those with higher peak scores (chi-square=4.3, p=.04). In
addition, patients with higher peak WAT-1 scores (≥3) had a longer opioid weaning period
(median (IQR)=13.0 (9.0-18.0) vs 8.0 (5.0-12.0) days; p=.004) as well as longer lengths of
mechanical ventilation (median (IQR)=11.7 (8.2-15.6) vs 6.9 (5.4-9.6) days; p<.001), PICU
stay (median (IQR)=17.0 (12.0-27.0) vs 10.5 (9.0-15.0) days; p<.001) and hospital stay
(median (IQR)=29.0 (19.0-42.0) vs 20.0 (14.0-28.0) days; p=.01) than those with scores of <3.
Pediatr Crit Care Med. Author manuscript; available in PMC 2009 November 10.
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There were no differences in WAT-1 scores or intensity rating related to receiving other nonopioid or sedative drugs during the weaning period.

Discussion
Within the context of a clinical trial where clinical parameters relating to analgesic and sedative
administration and patient response were prospectively recorded over the duration of therapy,
we were able to examine the psychometric properties of an instrument to quantify the
prevalence and severity of withdrawal symptoms in children at high risk for development of
iatrogenic withdrawal. From these data, we were able to construct a parsimonious instrument,
the WAT-1 and to demonstrate its preliminary concurrent and predictive validity. This is the
largest prospective investigation and most comprehensive analysis of opioid and
benzodiazepine withdrawal symptoms in critically ill children.
The factor structure of the WAT-1 conformed to the main expected symptom clusters of motor
disturbance, behavioral state disturbance, autonomic disturbance and gastrointestinal
symptoms.1;4;5 There were some differences in the frequency and pattern of symptoms based
on age, which is to be expected given the differences in physical maturation across the age
span of children in this study. Further research is needed to determine whether these differences
can be accommodated in a single withdrawal assessment tool or if different variants of the tool
for children of different age groups would provide better diagnostic accuracy.
The WAT-1 showed excellent sensitivity and specificity compared to NRS overall rating of
withdrawal severity and greater validity than intensity ratings as demonstrated by its better
performance in relation to known risk factors for iatrogenic withdrawal such as opioid exposure
and length of therapy. We were unable to investigate differences between opioid and
benzodiazepine withdrawal symptoms, since all patients received both drugs during the study.
However, the validity analysis suggests that the WAT-1 is better at detecting symptoms of
opioid rather than benzodiazepine withdrawal. This is not surprising given that benzodiazepine
withdrawal is often described as more subtle and with fewer symptoms.18
We were also unable to examine relationships between the speed of opioid or benzodiazepine
dose tapering and the emergence of withdrawal symptoms because of the variability of the
weaning pattern over the observation periods. These questions are best investigated in a clinical
trial with withdrawal as the primary endpoint, testing two or more distinct protocols for
achieving analgesia and sedation weaning. Although previous literature has suggested weaning
algorithms for children varying from 10-50% of the peak dose at 4-24 hourly intervals and the
addition or substitution of other drugs, 1;4;5;9 only one prospective trial used the NAS score
and found no difference when patients were converted from fentanyl to methadone and weaned
over a 5-day or 10-day period. 19 However, the NAS and its variants lacks sensitivity for the
PICU setting, 11 is burdensome (requiring 2 to four hourly assessments) and is subject to serial
bias.
This study has some limitations, the most significant of which is the incomplete independence
of the withdrawal symptom scoring and withdrawal intensity ratings. Although clinical
judgment is often termed a ‘tin standard’, no validated biomarkers of iatrogenic withdrawal
presently exist. The use of polypharmacy may also have confounded the analyses. However,
clinician judgment about a patient’s immediate medical needs rightly over-ride the need for
uniformity in practice required for instrument validation. Next, withdrawal symptom intensity
may have been related to the patient’s primary medical condition and we did not search for
these potential confounders. Lastly, the sample does not represent the entire population of
children experiencing withdrawal symptoms, and replications of this study are needed in
different samples and settings. However, in this initial study evaluating the psychometric

Pediatr Crit Care Med. Author manuscript; available in PMC 2009 November 10.

Franck et al.

Page 8

properties of an instrument, having a probability sample (sampling of people) is less important
than having the full range of symptom intensity (sampling of content) represented, as occurred
in this study.20
The main aims of a withdrawal assessment tool are to improve the detection and treatment of
withdrawal symptoms before they compromise the patient’s clinical condition. Since the NAS
was first shown to reduce the treatment time for neonates with prenatal drug exposure,10 the
superiority of an assessment tool over subjective clinical assessment has been assumed but
never established for other patient groups or settings. The lack of adequate measures of
iatrogenic withdrawal and the need for such tools to guide clinical practice has been repeatedly
highlighted.5;9;21 The WAT-1 is a significant improvement over previous withdrawal
symptom assessment scales in that it has fewer items that can be more objectively and feasibly
measured. It is performed only twice a day compared to the usual 6 to 12 times per day for
other symptom assessment scales, which increases the likelihood that it will be used in clinical
practice. The assessment of the WAT-1 parameters is easily integrated into the standard startof-shift nursing assessment. Training can be accomplished through brief written instruction
and bedside demonstration and, consistent with most clinical activities, we recommend
periodic training updates and inter-rater reliability checks. Further research is needed to
confirm the cut-off values for the diagnosis of withdrawal and decisions about treatment.
Trends and direction of movement in WAT-1 scores may be more important because of the
highly individualized effects of withdrawal symptoms on a patient’s clinical recovery.
In summary, iatrogenic withdrawal is a common side effect of prolonged sedation in criticallyill pediatric patients that requires better methods of assessment and monitoring. The WAT-1
shows excellent preliminary psychometric performance when used to assess clinically
important withdrawal symptoms in the PICU setting. It is also much simpler and efficient that
previous assessment methods. Further psychometric evaluation is needed in other at-risk
groups, such as neonatal intensive care unit patients.
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Figure 1. Receiver Operator Characteristic Curve: WAT-1 and NRS of withdrawal intensity1 (n
= 816)

Legend: Area under the curve: .944 ± .008 (SE), CI: .928 - .961, p < .001; WAT-1 score of 3
or higher had the best sensitivity and specificity in relation to NRS withdrawal intensity ratings
of 4 or higher (.872 and .880, respectively)
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Figure 2. Comparison of opioid exposure levels by WAT-1 scores. (n=83)

Legend: Panel a. Greater median cumulative opioid dose for WAT-1 3+ vs WAT-1 < 3 (p<.
002); Panel b. Longer median length of opioid treatment prior to tapering for WAT-1 3+ vs
WAT-1 < 3 (p<.04).
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Table 1

Demographic and clinical characteristics (n = 83)
Age in months; Median (IQR)
35 (7 - 121)
Age group in years; %
46
0-2
19
2-6
35
Over 6
Female; %
42
Race; %
50
African American
46
Caucasian
4
Other
PCPC > 1; %
33
POPC >1; %
40
PRISM III1; Median (IQR)
9 (6 -16)
1,2
Length of mechanical ventilation (days) ; Median (IQR) 9.9 (6.7 - 13.8)
Length of PICU stay (days)1,2; Median (IQR)
14 (10 - 23)
Total length of stay (days)1; Median (IQR)
25 (16 - 38)
IQR: Interquartile range;
PCPC: Pediatric Cerebral Performance Category;
POPC: Pediatric Overall Performance Category;
PRISM III: Pediatric Risk of Mortality Score.
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Table 2

Opioid and benzodiazepine exposure and weaning
Opioid treatment cumulative dose (mg/kg)1; Median (IQR)
48.2 (25.5-84.3)
Peak opioid dose (mg/kg) 1; Median (IQR)
7.6 (4.2-10.4)
Benzodiazepine treatment cumulative dose (mg/kg) 2; Median (IQR)
24.0 (10.5-62.3)
Peak benzodiazepine dose (mg/kg) 2; Median (IQR)
3.3 (1.9-8.1)
Length of opioid treatment prior to tapering (days); Median (IQR)
6 (5-17)
Length of benzodiazepine treatment prior to tapering (days); Median (IQR)
7 (2-21)
Length of opioid weaning (days from peak); Median (IQR)
11 (1-23)
Length of benzodiazepine weaning (days from peak); Median (IQR)
10 (2-24)
IQR: Interquartile range
1

Morphine equivalents

2

Midazolam equivalents
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Table 3

Withdrawal symptoms by age group
(adjusted for clustering of observations within site and patient; n=1040)
Overall
0-2 years
2.1 - 6 years
>6 years
From patient record, previous 12 hours % (CI)
Any loose /watery stools
20.1 (15.6,25.6) 18.4 (12.0,27.3) 19.9 (12.1, 30.9) 22.0 (14.5, 31.9)
Any vomiting/wretching/gagging
7.6 (4.5,12.6) 12.3 (6.5,22.5) 5.9 (2.5,13.4)
3.2 (1.3,7.6)
Temperature > 37.8°C
25.1 (19.3,31.9) 19.5 (12.0-30.2) 18.3 (11.2,28.4) 34.2 (23.8,46.3)
Respiratory rate often > baseline for this child
44.2 (37.0,51.8) 42.8 (31.7,54.7) 39.3 (25.6,54.8) 48.1 (35.7,60.7)
Required suctioning > 1 every 2 hrs
16.7 (11.5,23.6) 18.2 (9.7,31.3) 14.5 (7.1,27.4) 16.1 (9.1,26.9)
2 minute pre-stimulus observation % (CI)
15.8 (11.9,20.6) 17.8 (12.2,25.2) 12.9 (7.5,21.2) 14.9 (8.6,24.5)
State: SBS1≥ +1 or awake distressed
Tremor - moderate/severe
7.9 (5.1,12.0) 8.8 (4.6,16.0)
3.2 (1.0,9.7) 9.1 (4.5,17.3)
Any Sweating
13.2 (8.8,19.3) 13.3 (7.4,22.5) 7.0 (2.2,20.1) 15.9 (7.8,26.0)
Uncoordinated/repetitive movements - moderate/ severe
5.8 (3.8,8.8) 9.0 (5.7,14.0)
0.5 (0.1,3.9) 4.7 (2.0,10.5)
Yawning or sneezing - 2 or more times
9.1 (6.5,12.5) 9.9 (5.8,16.5) 13.4 (6.0,27.3) 6.1 (3.4,10.9)
1 minute stimulus observation % (CI)
8.2 (5.9,11.3) 10.6 (6.8,16.1) 10.2 (5.0,19.7)
4.7 (2.3,9.0)
Startle to touch - moderate/severe2
Pupils ≥ 4mm
19.3 (13.6,26.6) 13.3 (7.3,22.8) 19.5 (7.9,40.4) 25.7 (15.4,39.8)
Muscle tone - increased
16.6 (12.1,22.2) 21.1 (13.5,31.4) 9.7 (3.7,23.2) 14.7 (8.3,24.7)
17.6 (13.6,22.5) 20.9 (15.5,27.5) 15.6 (8.7,26.4) 15.0 (8.4,25.3)
State - SBS1 ≥+1 or awake and distressed
Tremor - moderate/severe
10.3 (7.2,14.5) 12.6 (7.2,21.0) 7.0 (2.5,18.3) 9.3 (5.2,16.0)
Any sweating
13.3 (8.7,19.4) 13.7 (7.8,22.9) 7.5 (2.6,20.0) 15.4 (7.4,29.4)
Uncoordinated/repetitive movements - Moderate/ Severe 7.5 (5.1,10.7) 10.8 (7.2,15.9) 4.0 (0.8,19.6) 5.4 (2.4,11.8)
Yawning or sneezing - 2 or more times
9.1 (6.5,12.4) 9.9 (5.8,16.5) 11.8 (5.1,25.1) 6.9 (3.8,12.1)
Post-stimulus recovery % (CI)
Time to gain calm state (SBS1 < 0) 14.6 (10.6,19.9) 20.2 (13.3,29.5) 10.2 (5.2,19.2) 10.6 (6.1,17.8)
2-5 minutes
5.7 (3.7,9.2) 6.7 (3.7,12.1) 3.8 (1.0,13.2) 5.9 (2.5,13.4)
> 5 minutes
Total Score
43.9
48.1
48.9
37.2
WAT-1 = 0 (%)3
1
17.2
10.6
17.7
24.2
2
13.6
11.2
14.0
15.9
3
8.6
7.9
8.6
9.3
4
6.1
7.2
4.8
5.4
5
3.6
3.6
3.2
3.7
6
3.6
5.4
1.6
2.4
7+
3.4
6.0
1.2
1.9
Total WAT-1 (Median, IQR)
1.0 (0.0-3.0)
1.0 (0.0-3.0)
1.0 (0.0-2.0)
1.0 (0.0-2.00
WAT-1 Peak (Median, IQR)
3.0 (2.0-6.0)
4.5 (2.0-7.0)
3.0 (1.5-5.0)
4.0 (2.0-6.0)
WAT-1: Withdrawal Assessment Tool - 1; CI: Confidence interval; IQR: Interquartile range
Bold = in final WAT-1; Non-bold/light shaded items = eliminated from WAT-1
1

Curley et al. State behavioral scale: A sedation assessment instrument for infants and young children supported on mechanical ventilation. Pediatr Crit
Care Med 2006;7(2):107-114.
2

Startle to touch: greater than 6 years < other age groups, p=.09

3

Total WAT-1 Score (%): greater than 6 years < other age groups, p=.0
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1 (WAT - 1) and Instructions

Table 4

No = 0
Yes = 1
No = 0
Yes = 1
No = 0
Yes = 1

Date:
Time:
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✓ Tremor: Score 1 if moderate to severe tremor observed during the 2 minutes prior to the stimulus; score 0 if no tremor (or only minor, intermittent tremor).

✓ State: Score 1 if awake and distress (SBS1: ≥ +1) observed during the 2 minutes prior to the stimulus; score 0 if asleep or awake and calm/cooperative (SBS1≤ 0).

2 minute pre-stimulus observation:

✓ Temperature > 37.8°C: Score 1 if the modal (most frequently occurring) temperature documented was greater than 37.8 °C in the past 12 hours; score 0 if this was not the case.

✓ Vomiting/wretching/gagging : Score 1 if any vomiting or spontaneous wretching or gagging were documented in the past 12 hours; score 0 if none were noted

✓ Loose/watery stools: Score 1 if any loose or watery stools were documented in the past 12 hours; score 0 if none were noted.

Obtain information from patient record (this can be done before or after the stimulus):

• The Withdrawal Assessment Tool (WAT-1) should be completed along with the SBS1 at least once per 12 hour shift (e.g., at 08:00 and 20:00 ± 2 hours). The progressive stimulus used in the
SBS1 assessment provides a standard stimulus for observing signs of withdrawal.

• Start WAT-1 scoring from the first day of weaning in patients who have received opioids +/or benzodiazepines by infusion or regular dosing for prolonged periods (e.g., > 5 days). Continue twice
daily scoring until 72 hours after the last dose.

- 1) INSTRUCTIONS

< 2min = 0
2 - 5min = 1
> 5 min = 2

None/mild = 0
Moderate/severe = 1
Normal = 0
Increased = 1

None/mild = 0
Moderate/severe = 1
No = 0
Yes = 1
None/mild = 0
Moderate/severe = 1
None or 1 = 0
≥2 = 1

SBS1≤ 0 or asleep/awake/calm = 0
SBS1≥ +1 or awake/distressed = 1

WITHDRAWAL ASSESSMENT TOOL(WAT

Total Score (0-12)

Post-stimulus recovery
Time to gain calm state (SBS1≤ 0)

Muscle tone

1 minute stimulus observation
Startle to touch

Yawning or sneezing

Uncoordinated/repetitive movement

Any sweating

Tremor

2 minute pre-stimulus observation
State

Temperature > 37.8°C

Any vomiting/wretching/gagging

Information from patient record, previous 12 hours
Any loose /watery stools

Patient Identifier

© 2007 L.S. Franck and M.A.Q. Curley. All Rights reserved. Reproduced by permission of Authors
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Sum the 11 numbers in the column for the total WAT-1 score (0-12).

Curley et al. State behavioral scale: A sedation assessment instrument for infants and young children supported on mechanical ventilation. Pediatr Crit Care Med 2006;7(2):107-114.

1

✓ Time to gain calm state (SBS1≤ 0): Score 2 if it takes greater than 5 minutes following stimulus; score 1 if achieved within 2 to 5 minutes; score 0 if achieved in less than 2 minutes.

Post-stimulus recovery:

✓ Muscle tone: Score 1 if tone increased during the stimulus; score 0 if normal.

✓ Startle to touch: Score 1 if moderate to severe startle occurs when touched during the stimulus; score 0 if none (or mild).

1 minute stimulus observation:

✓ Yawning or sneezing > 1: Score 1 if more than 1 yawn or sneeze observed during the 2 minutes prior to the stimulus; score 0 if 0 to 1 yawn or sneeze.

✓ Uncoordinated/repetitive movements: Score 1 if moderate to severe uncoordinated or repetitive movements such as head turning, leg or arm flailing or torso arching observed during the 2
minutes prior to the stimulus; score 0 if no (or only mild) uncoordinated or repetitive movements.

✓ Sweating: Score 1 if any sweating during the 2 minutes prior to the stimulus; score 0 if no sweating noted.
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